– May 1, 2012
May 1, 2012
View Issues
-
Cetuximab Adds No Benefit to Adjuvant Chemotherapy in Stage III Colon Cancer
This randomized Phase 3 clinical trial found that adding cetuximab to standard mFOLFOX6 adjuvant chemotherapy did not improve either overall survival or disease-free survival in patients with resected stage III colon cancer, including those with wild-type KRAS tumors. -
Occult Axillary Node Metastasis in Early-stage Breast Cancer: Important or Not?
In a retrospective review of 267 patients evaluated at M.D. Anderson Cancer Center with apparent early-stage, node-negative breast cancer, 15% were found to harbor "occult" metastases upon more intensive scrutiny of the axillary node specimens. In this series, long-term follow-up indicates that such discovery was not associated with a greater frequency of recurrence or poorer survival. -
Randomized, Double-Blind, Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System
In a small, single-institutional, prospective, randomized, placebo-controlled trial, 14 eligible patients (median age 47 years) with clinical and radiographic evidence of radiation necrosis secondary to prior head-and-neck or CNS irradiation were randomized to receive intravenous saline of bevacizumab at 3-week intervals. Patients were followed with serial MRI scans, neurologic examinations, and formal neuropsychological examinations. -
Solitary Colorectal Pulmonary Metastasis
A 61-year-old small business owner was seen in consultation for advice regarding management of a newly discovered pulmonary mass. Seven years previously, he had a 3.5 cm moderately differentiated adenocarcinoma of the sigmoid colon resected along with four regional nodes, all of which were negative for metastatic involvement. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.